Abstract:Neurorehabilitation and Neural Repair, Ahead of Print. BackgroundMicroglial-induced inflammation plays a crucial role in the pathophysiological process of nervous system injury, however, still lacks effective therapeutic agents. Previously, we discovered that the inhibition of histone deacetylase 3 (HDAC3) exerts anti-inflammatory effects after traumatic spinal cord injury (SCI), whereas little is known about its underlying mechanism. Therefore, the present study aimed to explore the effects and potential mechanisms of HDAC3 on neuroinflammation and microglial function.MethodsRats were randomized into 4 groups: sham group, SCI group, SCI + vehicle group, and SCI + RGF966 group. To examine the effect of HDAC3 on neurological deficit after SCI, we gathered data using the Basso Beattie Bresnahan locomotion scale, the inclined plane test, the blood-spinal cord barrier, junction protein expression, and Nissl staining. We also evaluated microglial activation and inflammatory factor levels. Immunofluorescence analysis, immunohistochemical analysis, western blotting, and quantitative real-time polymerase chain reaction were performed to examine the regulation of the Sirtuin 1 (SIRT1)/nuclear factor-erythroid 2-related factor 2 (Nrf2) pathway.ResultsThe results showed that HDAC3 inhibition significantly ameliorated Basso–Beattie–Bresnahan (BBB) permeability, brain edema, and improved neurological functions and junction protein levels. Additionally, HDAC3 inhibition significantly inhibited microglial activation, thereby reducing the levels of SCI-induced pro-inflammatory factors. Moreover, HDAC3 inhibition dramatically enhanced the expression of SIRT1 and increased both Nrf2 nuclear accumulation and transcriptional activity, thereby increasing downstream heme oxygenase-1 and NAD(P)H quinone oxidoreductase 1 expression.ConclusionsThe results of this study suggest that HDAC3 inhibition protects the spinal cord from injury following SCI by inhibiting SCI-induced microglial activation and the subsequent inflammatory response via SIRT1/Nrf2 signaling pathway, highlighting HDAC3 as a potential therapeutic target for the treatment of SCI.

A histone deacetylase 3–dependent pathway delimits peripheral myelin growth and functional regeneration

Comprehensive Mapping of 5-Hydroxymethylcytosine Epigenetic Dynamics in Axon Regeneration.

PP4-dependent HDAC3 dephosphorylation discriminates between axonal regeneration and regenerative failure

Histone methyltransferase Ezh2 coordinates mammalian axon regeneration via regulation of key regenerative pathways

HDAC-mediated Deacetylation of NF-κB is Critical for Schwann Cell Myelination

Suppression of Histone Deacetylation Promotes the Differentiation of Human Pluripotent Stem Cells Towards Neural Progenitor Cells.

The histone deacetylase complex MiDAC regulates a neurodevelopmental gene expression program to control neurite outgrowth

HDAC6 as a potential therapeutic target for peripheral nerve disorders

Roles of Kdm6a and Kdm6b in regulation of mammalian neural regeneration

Histone Deacetylase 3 Inhibition Ameliorates Microglia-Mediated Neuro-Inflammation Via the SIRT1/Nrf2 Pathway After Traumatic Spinal Cord Injury

Cbp-dependent histone acetylation mediates axon regeneration induced by environmental enrichment in rodent spinal cord injury models

Role of histone deacetylases and their inhibitors in neurological diseases

Subnetwork identification and chemical modulation for neural regeneration: A study combining network guided forest and heat diffusion model

HDAC Inhibitors Induce BDNF Expression and Promote Neurite Outgrowth in Human Neural Progenitor Cells-Derived Neurons

Promoting axon regeneration by inhibiting RNA N6-methyladenosine demethylase ALKBH5

Histone deacetylase 3 regulates microglial function through histone deacetylation

Loss of HDAC11 Ameliorates Clinical Symptoms in a Multiple Sclerosis Mouse Model.

Rationale for the Use of Histone Deacetylase Inhibitors as a Dual Therapeutic Modality in Multiple Sclerosis

Transcriptome Analysis of Schwann Cells at Various Stages of Myelination Implicates Chromatin Regulator Sin3A in Control of Myelination Identity

Regulation of Peripheral Nerve Myelin Maintenance by Gene Repression Through Polycomb Repressive Complex 2.

HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease